The Food and Drug Administration on Wednesday approved Valeant Pharmaceuticals International's psoriasis drug Siliq.
Siliq is an injectable drug intended to treat adults with moderate-to-severe plaque psoriasis, which causes patches of redness and flaking on the skin.
The drug's label includes a boxed warning about the risk of suicide, as some patients treated with the drug during clinical trials demonstrated suicidal behavior, according to the FDA.
Valeant expects Siliq to hit the market in the second half of 2017.
More articles on supply chain:
Winter storms exacerbate blood shortage in New England
Price controversy threatens Marathon CEO's seat on PhRMA board
7 must-reads for supply chain leaders this week